Neurogenic Bladder Disorder
13
1
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
1 terminated out of 13 trials
90.0%
+3.4% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 9 completed trials
Clinical Trials (13)
Turkish Version of the Neurogenic Bladder Symptom Score Short Form
Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients
Effects of Pelvic Floor Strengthening and Relaxation Exercises in Women Diagnosed With Multiple Sclerosis
Define Final Selection Choice Criteria for a Coloplast Catheter Ensuring Highest Patient Satisfaction Via Surveys (EVA).
Use of Wearables Following Cystectomy- Part II
Urinary Calculi After Bladder Augmentation in Children
Urinary Artificial Sphincter in Children
Bladder Neck Surgery in Children with Neurogenic Bladder
Complications of Bladder Augmentation in Children
Predictive Urodynamic Parameters for The Treatment Efficacy of Onabotulinum A Toxin in Neurogenic Lower Urinary Tract Dysfunction
Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions
Medico-economical Impact of the Brindley Neurosurgical Technique in France
Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity